Syra Health Stock Price, News & Analysis

Syra Health (OTCQB: SYRA) has achieved ISO 27001:2022 certification, demonstrating its commitment to information security management. This certification is particularly significant for the company's AI-backed mental health app, Syrenity, which handles sensitive user data.

The certification validates Syra Health's comprehensive framework for managing information security risks and comes alongside the company's proprietary Syra Guardrails framework for ethical AI use in healthcare. The certification was granted following an independent audit of the company's security systems and procedures.

Syra Health (OTCQB: SYRA) has been selected for contract negotiations to implement Indiana's Child Mental Health Wraparound Access Site. The contract, valued at $5.8 million over three years with a possible one-year extension, involves Syra Health serving as the statewide access point for families and providers navigating Indiana's Child Mental Health Wraparound program.

The company has committed to subcontracting 23.5% of the total contract value to other Indiana-based companies. Revenue recognition is expected later in 2025 after final contract execution. The initiative aims to strengthen care coordination and improve mental health outcomes for children across Indiana, leveraging Syra Health's integrated approach combining public health expertise, data analytics, and mental health support.

Syra Health Corp. (SYRA) announced that its Board of Directors is initiating a national search for a new Chief Executive Officer to replace current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO during the transition period and is expected to remain part of the leadership team after the appointment of her successor.

This leadership transition is described as part of a strategic succession plan aimed at positioning the healthcare technology company for its next growth phase. The Board emphasized its commitment to finding a leader who will advance the company's mission of delivering accessible, affordable, and prevention-focused healthcare solutions.

Syra Health (SYRA) reported Q1 2025 financial results with total revenue of $1.9 million, up 6% YoY. The company's Population Health segment showed remarkable growth, expanding 261% YoY to $1.2 million and representing 65% of total revenues. Gross margins improved significantly to 31.7%, up 14.6 percentage points YoY. Operating expenses decreased 39% YoY, leading to a reduced net loss of ($472,000), compared to ($1.4) million in Q1 2024. The company maintains a strong balance sheet with $2.5 million in cash and no long-term debt. Notable achievements include securing a $2.5 million Population Health contract with a major insurance provider and a $1.5 million contract extension with Indiana FSSA. However, due to federal government budgetary revisions affecting key customers, Syra Health has withdrawn its 2025 guidance.

Syra Health (OTCQB: SYRA), a healthcare technology company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before market open. The company will host a conference call at 9:00 a.m. ET on the same day to discuss the results. Investors can access the conference call via webcast through the company's investor relations website and submit questions via email. A replay of the webcast will be available in the investors section of Syra Health's website.

Syra Health Corp. (NASDAQ: SYRA) has announced its voluntary delisting from the Nasdaq Capital Market, with the last trading day expected around April 21, 2025. The decision follows the company's non-compliance with Nasdaq's minimum $1.00 bid price requirement, which was notified on October 18, 2024.

The healthcare technology company plans to file Form 25 with the SEC around April 11, 2025. Management views this as a strategic pause to focus on strengthening core fundamentals and reducing Nasdaq-associated costs. The company expects its common stock to transition to the OTC market and intends to maintain shareholder communication, though trading continuity is not guaranteed.

Syra Health (NASDAQ: SYRA) has secured a one-year, $660,000 Population Health contract extension with a national healthcare organization, bringing the total contract value to $1.32 million over two years.

The extension involves providing Healthcare Effectiveness Data and Information Set (HEDIS®) outreach and support services, focusing on improving healthcare quality, enhancing member outcomes, and reducing costs through data analysis and member outreach initiatives.

This renewal represents a continuation of services initially announced in March 2024 and supports the expansion of Syra Health's Population Health business unit, which is identified as a key growth contributor to the company's diversifying revenue base through higher-margin business segments.

Syra Health (NASDAQ: SYRA) reported strong financial results for FY2024, with revenue reaching $8.0 million, up 45% from $5.5 million in 2023. The company's Population Health segment showed remarkable growth, with revenues more than doubling to $1.7 million, while Healthcare Workforce revenue increased 38% to $5.9 million.

Q4 2024 showed significant operational improvements, with net losses nearly halving to ($504,000) from ($995,000) in Q4 2023, and operating expenses decreasing 39% YoY. The company maintained a strong balance sheet with $2.4 million in cash and no long-term debt as of December 31, 2024.

For 2025, Syra Health projects low double-digit percentage revenue growth, driven by higher-margin Population Health and Behavioral Health units. Recent achievements include positive preliminary results from the Syrenity app clinical study and several new contract wins and extensions with government agencies.

Syra Health (NASDAQ: SYRA), a healthcare technology company, has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, March 11, 2025, before market opening. The company will host a conference call at 9:00 a.m. ET on the same day to discuss the results.

Investors can access the conference call via webcast through the company's investor relations website. Those interested in submitting questions for the call can email them to corbin@haydenir.com. A replay of the webcast will be available in the investors section of Syra Health's website.